Compare WLY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLY | NVCR |
|---|---|---|
| Founded | 1807 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Books | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.0B |
| IPO Year | 1994 | 2015 |
| Metric | WLY | NVCR |
|---|---|---|
| Price | $48.68 | $16.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 446.4K | ★ 1.0M |
| Earning Date | 06-16-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 171.90 | 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,796,103,000.00 | $655,353,000.00 |
| Revenue This Year | $1.04 | $7.72 |
| Revenue Next Year | $2.36 | $6.74 |
| P/E Ratio | $11.58 | ★ N/A |
| Revenue Growth | 4.51 | ★ 8.28 |
| 52 Week Low | $28.38 | $9.82 |
| 52 Week High | $57.45 | $21.45 |
| Indicator | WLY | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 45.50 |
| Support Level | $37.37 | $16.33 |
| Resistance Level | $53.24 | $18.41 |
| Average True Range (ATR) | 2.17 | 0.80 |
| MACD | -0.55 | -0.08 |
| Stochastic Oscillator | 21.20 | 15.13 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning, which includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.